The company is selling approximately 8.93 million common shares at $37.50 each. To accommodate demand, underwriters hold a 30-day option to acquire an additional 1.6 million shares at the same price point, excluding standard commissions. For specific investors, Enliven is substituting common stock with pre-funded warrants for up to 1.73 million shares.
In section Market Quotes
Enliven Therapeutics Surges Following $400 Million Offering
Investors pushed Enliven Therapeutics shares up 15% to $46.37 on Friday, reacting to the clinical-stage biopharmaceutical firm’s decision to increase its public offering to $400 million. The company’s stock has now tripled in value since January, signaling significant market confidence in its pipeline and financial strategy.
Managed by a syndicate including Jefferies, Goldman Sachs, Morgan Stanley, and Barclays, the transaction is slated to close around Monday. This capital injection follows a period of rapid valuation growth for the firm, which has seen its market presence expand aggressively throughout the year.
Comments (0)
No comments yet. Be the first!